Skip to NavigationSkip to content

ESMO 2019

AZ's Tagrisso extends median overall survival by over 3 years in metastatic, EGFR-mutated lung cancer

AstraZeneca took to the stage at the 2019 European Society for Medical Oncology (ESMO) Congress in Barcelona to present new data on Tagrisso (osimertinib) in the first-line treatment of locally-advanced or metastatic epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC).

Tagrisso was shown to present a ‚Äústatistically significant and clinically meaningful improvement‚ÄĚ in overall survival, extending life by a median of 38.6 months compared to 31.8 months with previous standards of care gefitinib and erlotinib.

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches